APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sickle Cell Anemia Therapeutics

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Selected research

Market Outlook & Growth Opportunities

Global Sickle Cell Anemia Therapeutics Market Outlook and Growth Opportunities 2026

21 December 2025191 pages

Choose your research edition.

Industry ResearchSickle Cell Anemia Therapeutics Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Sickle Cell Anemia Therapeutics Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Sickle Cell Anemia Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sickle Cell Anemia Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Sickle Cell Anemia Therapeutics Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.

Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.

Read the full market overview

In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.

This report provides an overview of the global Sickle Cell Anemia Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sickle Cell Anemia Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sickle Cell Anemia Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Sickle Cell Anemia Therapeutics market.

Sickle Cell Anemia Therapeutics Segment by Company

Emmaus Medical

Addmedica

Gamida Cell

GlycoMimetics

Pfizer

Novartis

Global Blood Therapeutics

Micelle BioPharma

Bluebird Bio

Prolong Pharmaceuticals

Modus Therapeutics

Sangamo Biosciences

Bioverativ

Imara

Ironwood Pharmaceuticals

Sickle Cell Anemia Therapeutics Segment by Type

Blood Transfusion

Pharmacotherapy

Bone Marrow Transplant

Sickle Cell Anemia Therapeutics Segment by Application

Child

Adult

Sickle Cell Anemia Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Sickle Cell Anemia Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Sickle Cell Anemia Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Sickle Cell Anemia Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Sickle Cell Anemia Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sickle Cell Anemia Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Sickle Cell Anemia Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Anemia Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Anemia Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Anemia Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sickle Cell Anemia Therapeutics industry.

Chapter 3: Detailed analysis of Sickle Cell Anemia Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Sickle Cell Anemia Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Sickle Cell Anemia Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sickle Cell Anemia Therapeutics Industry Trends Table 2. Sickle Cell Anemia Therapeutics Industry Drivers Table 3. Sickle Cell Anemia Therapeutics Industry Opportunities and Challenges Table 4. Sickle Cell Anemia Therapeutics Industry Restraints Table 5. Global Sickle Cell Anemia Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sickle Cell Anemia Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Sickle Cell Anemia Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Sickle Cell Anemia Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Sickle Cell Anemia Therapeutics Company, Product Type & Application Table 10. Global Sickle Cell Anemia Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Sickle Cell Anemia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Blood Transfusion Table 15. Significant Companies of Pharmacotherapy Table 16. Significant Companies of Bone Marrow Transplant Table 17. Global Sickle Cell Anemia Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Sickle Cell Anemia Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Sickle Cell Anemia Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Sickle Cell Anemia Therapeutics Sales Value Share by Type (2021-2026) Table 21. Global Sickle Cell Anemia Therapeutics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Child Table 23. Significant Companies of Adult Table 24. Global Sickle Cell Anemia Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Sickle Cell Anemia Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Sickle Cell Anemia Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Sickle Cell Anemia Therapeutics Sales Value Share by Application (2021-2026) Table 28. Global Sickle Cell Anemia Therapeutics Sales Value Share by Application (2027-2032) Table 29. Global Sickle Cell Anemia Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Sickle Cell Anemia Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Sickle Cell Anemia Therapeutics Sales Value Share by Region (2021-2026) Table 32. Global Sickle Cell Anemia Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Sickle Cell Anemia Therapeutics Sales Value Share by Region (2027-2032) Table 34. Global Sickle Cell Anemia Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Sickle Cell Anemia Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Sickle Cell Anemia Therapeutics Sales Value Market Share by Country (2021-2026) Table 37. Global Sickle Cell Anemia Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Sickle Cell Anemia Therapeutics Sales Value Market Share by Country (2027-2032) Table 39. Emmaus Medical Company Information Table 40. Emmaus Medical Business Overview Table 41. Emmaus Medical Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Emmaus Medical Sickle Cell Anemia Therapeutics Product Portfolio Table 43. Emmaus Medical Recent Development Table 44. Addmedica Company Information Table 45. Addmedica Business Overview Table 46. Addmedica Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Addmedica Sickle Cell Anemia Therapeutics Product Portfolio Table 48. Addmedica Recent Development Table 49. Gamida Cell Company Information Table 50. Gamida Cell Business Overview Table 51. Gamida Cell Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Gamida Cell Sickle Cell Anemia Therapeutics Product Portfolio Table 53. Gamida Cell Recent Development Table 54. GlycoMimetics Company Information Table 55. GlycoMimetics Business Overview Table 56. GlycoMimetics Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. GlycoMimetics Sickle Cell Anemia Therapeutics Product Portfolio Table 58. GlycoMimetics Recent Development Table 59. Pfizer Company Information Table 60. Pfizer Business Overview Table 61. Pfizer Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Pfizer Sickle Cell Anemia Therapeutics Product Portfolio Table 63. Pfizer Recent Development Table 64. Novartis Company Information Table 65. Novartis Business Overview Table 66. Novartis Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novartis Sickle Cell Anemia Therapeutics Product Portfolio Table 68. Novartis Recent Development Table 69. Global Blood Therapeutics Company Information Table 70. Global Blood Therapeutics Business Overview Table 71. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio Table 73. Global Blood Therapeutics Recent Development Table 74. Micelle BioPharma Company Information Table 75. Micelle BioPharma Business Overview Table 76. Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Micelle BioPharma Sickle Cell Anemia Therapeutics Product Portfolio Table 78. Micelle BioPharma Recent Development Table 79. Bluebird Bio Company Information Table 80. Bluebird Bio Business Overview Table 81. Bluebird Bio Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Bluebird Bio Sickle Cell Anemia Therapeutics Product Portfolio Table 83. Bluebird Bio Recent Development Table 84. Prolong Pharmaceuticals Company Information Table 85. Prolong Pharmaceuticals Business Overview Table 86. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio Table 88. Prolong Pharmaceuticals Recent Development Table 89. Modus Therapeutics Company Information Table 90. Modus Therapeutics Business Overview Table 91. Modus Therapeutics Sickle Cell Anemia Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. Modus Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio Table 93. Modus Therapeutics Recent Development Table 94. Sangamo Biosciences Company Information Table 95. Sangamo Biosciences Business Overview Table 96. Sangamo Biosciences Sickle Cell Anemia Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. Sangamo Biosciences Sickle Cell Anemia Therapeutics Product Portfolio Table 98. Sangamo Biosciences Recent Development Table 99. Bioverativ Company Information Table 100. Bioverativ Business Overview Table 101. Bioverativ Sickle Cell Anemia Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. Bioverativ Sickle Cell Anemia Therapeutics Product Portfolio Table 103. Bioverativ Recent Development Table 104. Imara Company Information Table 105. Imara Business Overview Table 106. Imara Sickle Cell Anemia Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. Imara Sickle Cell Anemia Therapeutics Product Portfolio Table 108. Imara Recent Development Table 109. Ironwood Pharmaceuticals Company Information Table 110. Ironwood Pharmaceuticals Business Overview Table 111. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 112. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio Table 113. Ironwood Pharmaceuticals Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Sickle Cell Anemia Therapeutics Product Image Figure 2. Global Sickle Cell Anemia Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sickle Cell Anemia Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Sickle Cell Anemia Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Blood Transfusion Image Figure 8. Pharmacotherapy Image Figure 9. Bone Marrow Transplant Image Figure 10. Global Sickle Cell Anemia Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Sickle Cell Anemia Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Sickle Cell Anemia Therapeutics Sales Value Share by Type (2021-2032) Figure 13. Child Image Figure 14. Adult Image Figure 15. Global Sickle Cell Anemia Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Sickle Cell Anemia Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Sickle Cell Anemia Therapeutics Sales Value Share by Application (2021-2032) Figure 18. Global Sickle Cell Anemia Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Sickle Cell Anemia Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Sickle Cell Anemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Sickle Cell Anemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Sickle Cell Anemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Sickle Cell Anemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Sickle Cell Anemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Sickle Cell Anemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Sickle Cell Anemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Sickle Cell Anemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Transfusion
  • Pharmacotherapy
  • Bone Marrow Transplant
Applications
  • Child
  • Adult
Companies covered
  • Emmaus Medical
  • Addmedica
  • Gamida Cell
  • GlycoMimetics
  • Pfizer
  • Novartis
  • Global Blood Therapeutics
  • Micelle BioPharma
  • Bluebird Bio
  • Prolong Pharmaceuticals
  • Modus Therapeutics
  • Sangamo Biosciences
  • Bioverativ
  • Imara
  • Ironwood Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sickle Cell Anemia Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sickle Cell Anemia Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Sickle Cell Anemia Therapeutics Market Dynamics
  1. 2.1 Sickle Cell Anemia Therapeutics Industry Trends
  2. 2.2 Sickle Cell Anemia Therapeutics Industry Drivers
  3. 2.3 Sickle Cell Anemia Therapeutics Industry Opportunities and Challenges
  4. 2.4 Sickle Cell Anemia Therapeutics Industry Restraints
3 Sickle Cell Anemia Therapeutics Market by Company
  1. 3.1 Global Sickle Cell Anemia Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Sickle Cell Anemia Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Sickle Cell Anemia Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Sickle Cell Anemia Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Sickle Cell Anemia Therapeutics Company Product Type and Application
  6. 3.6 Global Sickle Cell Anemia Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Sickle Cell Anemia Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Sickle Cell Anemia Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Sickle Cell Anemia Therapeutics Market by Type
  1. 4.1 Sickle Cell Anemia Therapeutics Type Introduction
  2. 4.1.1 Blood Transfusion
  3. 4.1.2 Pharmacotherapy
  4. 4.1.3 Bone Marrow Transplant
  5. 4.2 Global Sickle Cell Anemia Therapeutics Sales Value by Type
  6. 4.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Sickle Cell Anemia Therapeutics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Sickle Cell Anemia Therapeutics Sales Value Share by Type (2021-2032)
5 Sickle Cell Anemia Therapeutics Market by Application
  1. 5.1 Sickle Cell Anemia Therapeutics Application Introduction
  2. 5.1.1 Child
  3. 5.1.2 Adult
  4. 5.2 Global Sickle Cell Anemia Therapeutics Sales Value by Application
  5. 5.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Sickle Cell Anemia Therapeutics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Sickle Cell Anemia Therapeutics Sales Value Share by Application (2021-2032)
6 Sickle Cell Anemia Therapeutics Regional Value Analysis
  1. 6.1 Global Sickle Cell Anemia Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sickle Cell Anemia Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Sickle Cell Anemia Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sickle Cell Anemia Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Sickle Cell Anemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Sickle Cell Anemia Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Sickle Cell Anemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Sickle Cell Anemia Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Sickle Cell Anemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Sickle Cell Anemia Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Sickle Cell Anemia Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Sickle Cell Anemia Therapeutics Country-level Value Analysis
  1. 7.1 Global Sickle Cell Anemia Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sickle Cell Anemia Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Sickle Cell Anemia Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Sickle Cell Anemia Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Sickle Cell Anemia Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Sickle Cell Anemia Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Emmaus Medical
  2. 8.1.1 Emmaus Medical Company Information
  3. 8.1.2 Emmaus Medical Business Overview
  4. 8.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Product Portfolio
  6. 8.1.5 Emmaus Medical Recent Developments
  7. 8.2 Addmedica
  8. 8.2.1 Addmedica Company Information
  9. 8.2.2 Addmedica Business Overview
  10. 8.2.3 Addmedica Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Addmedica Sickle Cell Anemia Therapeutics Product Portfolio
  12. 8.2.5 Addmedica Recent Developments
  13. 8.3 Gamida Cell
  14. 8.3.1 Gamida Cell Company Information
  15. 8.3.2 Gamida Cell Business Overview
  16. 8.3.3 Gamida Cell Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gamida Cell Sickle Cell Anemia Therapeutics Product Portfolio
  18. 8.3.5 Gamida Cell Recent Developments
  19. 8.4 GlycoMimetics
  20. 8.4.1 GlycoMimetics Company Information
  21. 8.4.2 GlycoMimetics Business Overview
  22. 8.4.3 GlycoMimetics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlycoMimetics Sickle Cell Anemia Therapeutics Product Portfolio
  24. 8.4.5 GlycoMimetics Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Sickle Cell Anemia Therapeutics Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Sickle Cell Anemia Therapeutics Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Global Blood Therapeutics
  38. 8.7.1 Global Blood Therapeutics Company Information
  39. 8.7.2 Global Blood Therapeutics Business Overview
  40. 8.7.3 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio
  42. 8.7.5 Global Blood Therapeutics Recent Developments
  43. 8.8 Micelle BioPharma
  44. 8.8.1 Micelle BioPharma Company Information
  45. 8.8.2 Micelle BioPharma Business Overview
  46. 8.8.3 Micelle BioPharma Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Micelle BioPharma Sickle Cell Anemia Therapeutics Product Portfolio
  48. 8.8.5 Micelle BioPharma Recent Developments
  49. 8.9 Bluebird Bio
  50. 8.9.1 Bluebird Bio Company Information
  51. 8.9.2 Bluebird Bio Business Overview
  52. 8.9.3 Bluebird Bio Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bluebird Bio Sickle Cell Anemia Therapeutics Product Portfolio
  54. 8.9.5 Bluebird Bio Recent Developments
  55. 8.10 Prolong Pharmaceuticals
  56. 8.10.1 Prolong Pharmaceuticals Company Information
  57. 8.10.2 Prolong Pharmaceuticals Business Overview
  58. 8.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio
  60. 8.10.5 Prolong Pharmaceuticals Recent Developments
  61. 8.11 Modus Therapeutics
  62. 8.11.1 Modus Therapeutics Company Information
  63. 8.11.2 Modus Therapeutics Business Overview
  64. 8.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Product Portfolio
  66. 8.11.5 Modus Therapeutics Recent Developments
  67. 8.12 Sangamo Biosciences
  68. 8.12.1 Sangamo Biosciences Company Information
  69. 8.12.2 Sangamo Biosciences Business Overview
  70. 8.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Product Portfolio
  72. 8.12.5 Sangamo Biosciences Recent Developments
  73. 8.13 Bioverativ
  74. 8.13.1 Bioverativ Company Information
  75. 8.13.2 Bioverativ Business Overview
  76. 8.13.3 Bioverativ Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bioverativ Sickle Cell Anemia Therapeutics Product Portfolio
  78. 8.13.5 Bioverativ Recent Developments
  79. 8.14 Imara
  80. 8.14.1 Imara Company Information
  81. 8.14.2 Imara Business Overview
  82. 8.14.3 Imara Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Imara Sickle Cell Anemia Therapeutics Product Portfolio
  84. 8.14.5 Imara Recent Developments
  85. 8.15 Ironwood Pharmaceuticals
  86. 8.15.1 Ironwood Pharmaceuticals Company Information
  87. 8.15.2 Ironwood Pharmaceuticals Business Overview
  88. 8.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product Portfolio
  90. 8.15.5 Ironwood Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst